Where Will LLY Be in 5 Years?

Back in 2023 and 2024, share prices in Eli Lilly (NYSE: LLY) skyrocketed over investor excitement surrounding the potential of the pharmaceutical company's GLP-1 diabetes treatments and weight loss therapies. But since that initial enthusiasm wore off roughly 15 months ago, it's been a different story: Since mid-2024, share prices have stayed rangebound, trading for between $700 and $900 each.Lately, issues like tariffs have affected price performance, but valuation concerns have likely contributed the most to the stock's less-than-stellar performance during this time frame. Shares currently trade at a forward price-to-earnings (P/E) ratio of around 27. For comparison, Novo Nordisk (NYSE: NVO), another pharma stock benefiting from the GLP-1 trend, trades for only 14 times forward earnings.While Lilly may appear pricey compared to current results, don't rule out the chances of this stock doing more than just catching up to its valuation over the next five years.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool